Scopolamine

DRUG INFORMATION

  ADULT
    - Application and Removal ( 2.1 ): • Each TRANSDERM SCŌP transdermal system delivers
      1 mg of scopolamine over 3 days. • Only wear one transdermal system at a time. •
      Do not cut the transdermal system. • Wash hands thoroughly with soap and water
      after application. • Avoid touching or applying pressure to the transdermal system
      once applied.
      Source: US FDA label for scopolamine (Transderm Scop), section 'dosage and
      administration', retrieved 2026-08-29
    - ( 2.2 ) 2.1 Important Application and Removal Instructions • Each TRANSDERM SCŌP
      transdermal system is formulated to deliver in vivo approximately 1 mg of
      scopolamine over 3 days. • Only wear one transdermal system at any time. • Do not
      cut the transdermal system. • Apply the transdermal system to the skin in the
      postauricular area (hairless area behind one ear).
      Source: US FDA label for scopolamine (Transderm Scop), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - The safety and effectiveness of TRANSDERM SCŌP have not been established in
      pediatric patients. Pediatric patients are particularly susceptible to the
      anticholinergic adverse reactions of scopolamine, including neurologic and
      psychiatric adverse reactions and drug withdrawal syndrome.
      Source: US FDA label for scopolamine (Transderm Scop), section 'pediatric use',
      retrieved 2026-08-29
    - Application and Removal ( 2.1 ): • Each TRANSDERM SCŌP transdermal system delivers
      1 mg of scopolamine over 3 days. • Only wear one transdermal system at a time. •
      Do not cut the transdermal system. • Wash hands thoroughly with soap and water
      after application. • Avoid touching or applying pressure to the transdermal system
      once applied.
      Source: US FDA label for scopolamine (Transderm Scop), section 'dosage and
      administration', retrieved 2026-08-29
    - ( 2.2 ) 2.1 Important Application and Removal Instructions • Each TRANSDERM SCŌP
      transdermal system is formulated to deliver in vivo approximately 1 mg of
      scopolamine over 3 days. • Only wear one transdermal system at any time. • Do not
      cut the transdermal system. • Apply the transdermal system to the skin in the
      postauricular area (hairless area behind one ear).
      Source: US FDA label for scopolamine (Transderm Scop), section 'dosage and
      administration', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - No kidney-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for scopolamine (Transderm Scop),
      retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - ( 5.2 , 8.5 ) • Renal or Hepatic Impairment : Consider more frequent monitoring
      during treatment due to increased risk of CNS adverse reactions.
      Source: US FDA label for scopolamine (Transderm Scop), section 'use in specific
      populations', retrieved 2026-08-29
    - Advise patients if body temperature increases, or they are not sweating in warm
      environmental conditions, to remove the transdermal system and contact their
      healthcare provider [see Warnings and Precautions ( 5.5 )] . 8.6 Renal or Hepatic
      Impairment TRANSDERM SCŌP has not been studied in patients with renal or hepatic
      impairment.
      Source: US FDA label for scopolamine (Transderm Scop), section 'use in specific
      populations', retrieved 2026-08-29
    - Consider more frequent monitoring during treatment with TRANSDERM SCŌP in patients
      with renal or hepatic impairment because of the increased risk of CNS adverse
      reactions [see Warnings and Precautions ( 5.2 )].
      Source: US FDA label for scopolamine (Transderm Scop), section 'use in specific
      populations', retrieved 2026-08-29

  PREGNANCY
    - Risk Summary Eclamptic seizures have been reported in pregnant women with severe
      preeclampsia soon after injection of intravenous or intramuscular scopolamine.
      Source: US FDA label for scopolamine (Transderm Scop), section 'pregnancy',
      retrieved 2026-08-29
    - Avoid use of TRANSDERM SCOP in patients with severe preeclampsia [see Warnings and
      Precautions ( 5.3 ) and Data] .
      Source: US FDA label for scopolamine (Transderm Scop), section 'pregnancy',
      retrieved 2026-08-29
    - Available data from observational studies and postmarketing reports with
      scopolamine use in pregnant women have not identified a drug associated risk of
      major birth defects, miscarriage, or adverse fetal outcomes.
      Source: US FDA label for scopolamine (Transderm Scop), section 'pregnancy',
      retrieved 2026-08-29

  BREASTFEEDING
    - Scopolamine administered parenterally to rats and rabbits at doses higher than the
      dose delivered by TRANSDERM SCŌP did not affect uterine contractions or increase
      the duration of labor. 8.2 Lactation Risk Summary Scopolamine is present in human
      milk.
      Source: US FDA label for scopolamine (Transderm Scop), section 'use in specific
      populations', retrieved 2026-08-29
    - There are no available data on the effects of scopolamine on the breastfed infant
      or the effects on milk production.
      Source: US FDA label for scopolamine (Transderm Scop), section 'use in specific
      populations', retrieved 2026-08-29
    - The developmental and health benefits of breastfeeding should be considered along
      with the mother’s clinical need for TRANSDERM SCŌP and any potential adverse
      effects on the breastfed child from TRANSDERM SCŌP or from the underlying maternal
      condition. 8.4 Pediatric Use The safety and effectiveness of TRANSDERM SCŌP have
      not been established in pediatric patients.
      Source: US FDA label for scopolamine (Transderm Scop), section 'use in specific
      populations', retrieved 2026-08-29